Доктор Вялов Сергей Сергеевич – опытный гастроэнтеролог, гепатолог, кандидат медицинских наук. Автор более 160 научных статей, в том числе около 20 зарубежных книг для врачей и пациентов. 12-е место в рейтинге Comcon research среди врачей-экспертов. Руководитель федеральных образовательных программ. Инстаграм-блогер @DoctorVyalov.
• EASL – Европейское общество по изучению печени.
Автор образовательного курса «Просто Про Пищеварение», созданного с использованием технологий дополненной реальности. «Мы не даем решение, мы даем понимание. Вы понимаете сами, и решение становится очевидным».
Сергей Вялов курирует открытый проект для пациентов «Наболевшие вопросы», где все желающие получают ответы бесплатно. Официальный сайт: www.vyalov.com.
Список использованной литературы
Часть 2. Глава 2
1. Guy C.D., Suzuki A., Zdanowicz M. et al. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology. 2012 Jun. 55 (6): 1711–1721.
2. Adams L.A., Lymp J.F., St Sauver J. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul. 129 (1): 113–121.
3. Yeh M.M., Brunt E.M. Pathological features of fatty liver disease. Gastroenterology. 2014 Oct. 147 (4): 754–764.
4. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan. 67 (1): 328–357.
5. Kim D., Choi S.Y., Park E.H. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012 Aug. 56 (2): 605–613.
6. Garcia-Galiano D., Sanchez-Garrido M.A., Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007 Apr. 17 (4): 493–503.
7. Promrat K., Kleiner D.E., Niemeier H.M. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 Jan. 51 (1): 121–129.
8. Yamamoto M., Iwasa M., Iwata K. et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007 Apr. 22 (4): 498–503.
9. Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011 Mar. 106 (3): 460–468; quiz 469.
Часть 2. Глава 3
1. Casanova J., Bataller R. Alcoholic hepatitis: prognosis and treatment. Gastroenterol Hepatol. 2014 Apr. 37 (4): 262–268.
2. [Guideline] O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology. 2010 Jan. 51 (1): 307–328.
3. [Guideline] Singal A.K., Bataller R., Ahn J., Kamath P.S., Shah V.H. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb. 113 (2): 175–194.
4. Mihas A.A., Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci. 1992 Jun. 303 (6): 415–428.
5. Lucey M.R. Management of alcoholic liver disease. Clin Liver Dis. 2009 May. 13 (2): 267–275.
6. Rahimi E, Pan JJ. Prognostic models for alcoholic hepatitis. Biomark Res. 2015 Jul 21. 3: 20.
7. Llopis M., Cassard A.M., Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016 May. 65 (5): 830–839.
8. Mitchell M.C., Friedman L.S., McClain C.J. Medical management of severe alcoholic hepatitis: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Jan. 15 (1): 5–12.
Часть 2. Глава 4
1. [Guideline] Lee W.M., Larson A.M., Stravitz R.T. AASLD position paper: the management of acute liver failure: update 2011. Hepatology.
2. Khandelwal N., James L.P., Sanders C., Larson A.M., Lee W.M. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011 Feb. 53 (2):567-76.
3. Alempijevic T., Zec S., Milosavljevic T. Drug-induced liver injury: do we know everything? World J Hepatol. 2017 Apr 8. 9 (10):491–502.
4. Marrone G., Vaccaro F.G., Biolato M. et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci. 2017 Mar. 21 (1 Suppl):122-34.
5. Lo Re V. 3rd, Haynes K., Forde K.A. et al. Risk of acute liver failure in patients with drug-inducedliver injury: evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol. 2015 Dec. 13 (13): 2360–2368.
